The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
EARLY_PHASE1
MIMIGA Study
Title:
Modification of Intestinal Microbiome in Patients wit...
Longitudinal Evaluation of Short-Chain Fatty Acid Profiles During the Natural Disease Course and a Mediterranean Diet Intervention in Amyotrophic Lateral Sclerosis Patients
N/A
This observational study explored the connection between the gut microbiota...
Status
Completed
Location
University of Medicine, Pharmacy, Science and Technology of Târgu Mureș 'George Emil Palade'